Dual-Action Peptide for SARS-CoV-2, Respiratory Care
A Dual-Functional Antiviral Peptide Inhibits Two Entry Pathways of SARS-CoV-2
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology introduces a dual-functional antiviral peptide, 8P9R, which inhibits SARS-CoV-2 by blocking two viral entry pathways: TMPRSS2-mediated and endocytic. The peptide cross-links viruses on the cell surface and inhibits endosomal acidification, effectively preventing viral entry. In vivo studies demonstrate its efficacy against SARS-CoV-2 and SARS-CoV without notable toxicity in mouse lungs. Applications include therapeutics for COVID-19 and other respiratory virus-related diseases, addressing an urgent global health need. Protected by a US provisional patent application, this innovation offers a broad-spectrum antiviral solution for respiratory infections.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Biotechnology
